We detect DNA from dying neurons—a blood biomarker of neurodegeneration

Monitor cell-specific biomarkers of neurodegeneration with our screening tools.

The Current Gap

Early detection and intervention hold tremendous promise for altering the course of neurodegenerative diseases and reducing their impact. Yet current approaches to detecting disease, such as clinical assessments, neuroimaging, and cerebrospinal fluid (CSF) analysis, are often applied too late and remain invasive or difficult to access. This underscores the need for new tools to enable earlier detection, ongoing monitoring, and support for clinical research.

Informed Science

Misdiagnoses and diagnostic delays are common in neurodegenerative conditions, especially early in disease progression.

Up to 75% of individuals with dementia, including Alzheimer’s disease, go undiagnosed.1

ALS diagnoses are delayed by an average of 9 to 24 months after symptom onset.2 

By the time Parkinson’s symptoms appear, 40–60% of dopamine neurons may already be lost.3

Blood Test Advantages

Resonant is developing a non-invasive, accessible tool to support earlier detection and monitoring of neurodegeneration.

Our goal is to enable clinicians and researchers to track cell type–specific neuron loss, with potential applications as a companion tool in clinical trials and therapeutic development. By addressing current limitations in the diagnostic landscape, we aim to provide a scalable solution that adds precision and insight to neurodegenerative disease research.

Less Invasive

Uses a standard blood draw—no spinal tap or imaging required.

Accessible

Designed for physician ordering beyond major medical centers.

Cost Effective

Supports high-throughput processing for broader use.

Thorough

Detects neuron-derived cfDNA using proprietary methods. 

Our Approach

1. Identify neuron type-specific methylation patterns

Analyze plasma, public datasets, and whole-genome methylation data to identify DNA regions with cell type-specific methylation patterns.

2. Validate cell type identification via methylation analysis

Compare methylation at target regions in purified neurons and plasma to confirm neuron type identification is feasible.

3. Assess association between neuron-derived DNA and disease

Analyze plasma from affected individuals to determine if elevated neuron-derived DNA correlates with disease.

4. Optimize assay performance

Refine the protocol for improved cost-efficiency and scalability using NGS 3.0 and proprietary methods.

5. Expand validation to strengthen robustness

Conduct follow-up studies to refine assay performance, confirm specificity, control for comorbidities, and evaluate other potential confounding factors.

For more details about our clinical validation data:

Fill Out The Form
References & Citations

1: Gauthier, S., Rosa-Neto, P., Morais, J. A., & Webster, C. (2021). World Alzheimer Report 2021: Journey through the diagnosis of dementia. Alzheimer’s Disease International, 2022, 30.

2: Segura, T., Medrano, I. H., Collazo, S., Maté, C., Sguera, C., Del Rio-Bermudez, C., ... & Taberna, M. (2023). Symptoms timeline and outcomes in amyotrophic lateral sclerosis using artificial intelligence. Scientific Reports, 13(1), 702.

3: Giguère, N., Burke Nanni, S., & Trudeau, L. E. (2018). On cell loss and selective vulnerability of neuronal populations in Parkinson's disease. Frontiers in neurology, 9, 383041.

The ScienceProvidersIndividualsBiopharmaAbout Us
Copyright © 2024, All rights reserved

Sign Up For Our Newsletter

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.